Deutsche Bank
CRVS icon

Deutsche Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Deutsche Bank’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
74,529
+20,050
+37% +$278K ﹤0.01% 2289
2026
Q1 		$797K Sell
54,479
-1,560
-3% -$24.9K ﹤0.01% 2317
2025
Q4 		$432K Buy
56,039
+2,400
+4% +$18.9K ﹤0.01% 2654
2025
Q3 		$395K Buy
53,639
+9,651
+22% +$49.4K ﹤0.01% 2677
2025
Q2 		$176K Buy
+43,988
New +$160K ﹤0.01% 3031
2019
Q4 		– Sell
-337
Closed -$1K – 5001
2019
Q3 		$1K Sell
337
-118,299
-100% -$496K ﹤0.01% 4803
2019
Q2 		$442K Sell
118,636
-69,414
-37% -$272K ﹤0.01% 3350
2019
Q1 		$754K Sell
188,050
-19,732
-9% -$83.3K ﹤0.01% 3176
2018
Q4 		$762K Buy
207,782
+148,493
+250% +$1.01M ﹤0.01% 3059
2018
Q3 		$509K Buy
59,289
+24,636
+71% +$246K ﹤0.01% 3772
2018
Q2 		$381K Sell
34,653
-80,915
-70% -$903K ﹤0.01% 3985
2018
Q1 		$1.33M Buy
115,568
+96,510
+506% +$913K ﹤0.01% 3135
2017
Q4 		$196K Buy
19,058
+10,320
+118% +$132K ﹤0.01% 4037
2017
Q3 		$138K Sell
8,738
-1,149
-12% -$15.9K ﹤0.01% 4046
2017
Q2 		$119K Sell
9,887
-3,233
-25% -$34.5K ﹤0.01% 4149
2017
Q1 		$271K Buy
13,120
+11,128
+559% +$174K ﹤0.01% 3421
2016
Q4 		$27K Buy
1,992
+1,444
+264% +$22K ﹤0.01% 4524
2016
Q3 		$9K Sell
548
-2,912
-84% -$42K ﹤0.01% 4682
2016
Q2 		$49K Buy
+3,460
New +$46.7K ﹤0.01% 4421

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deutsche Bank's CRVS Position: Q2 2026 in Review

Deutsche Bank increased its Corvus Pharmaceuticals (CRVS) stake by 37% in Q2 2026, buying an estimated $278K and bringing the position to 74,529 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Deutsche Bank first reported a position in CRVS in Q2 2016 and has held it in 19 quarters since. The position peaked at $1.33M in Q1 2018. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Deutsche Bank held 74,529 shares of Corvus Pharmaceuticals worth $1.11M as of Q2 2026.
  • Deutsche Bank bought 20,050 Corvus Pharmaceuticals shares in Q2 2026, an estimated $278K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2289 holding.
  • Deutsche Bank first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 19 quarters since.
  • Deutsche Bank's Corvus Pharmaceuticals position peaked at $1.33M in Q1 2018.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.